Drugs / Glycopyrrolate/Formoterol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03324607 | Apr 2018 → Nov 2019 | chronic obstructive pulmonary disease | Bastiaan Driehuys | Completed | Met primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2020-05-18 | AstraZeneca | Regulatory Bevespi Aerosphere approved in China for patients with COPD astrazeneca.com ↗
AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. |
| 2019-08-28 | AstraZeneca | Results Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease astrazeneca.com ↗
At the standard budesonide dose, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6mcg) demonstrated a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies Bevespi Aerosphere (glycopyrronium/formoterol fumarate 14.4/9.6mcg) and PT009 (budesonide/formoterol fumarate 320/9.6mcg). |
| 2018-05-16 | AstraZeneca | Results AstraZeneca is advancing clinical practice in respiratory medicine with new data at the American Thoracic Society 2018 International Congress astrazeneca.com ↗
Glycopyrrolate/formoterol fumarate fixed-dose combination delivered by metered dose inhaler improves lung function and symptoms in patients with COPD: Results from the PINNACLE-4 Study in Asia, Europe, and the USA |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-05-18 | AstraZeneca | Bevespi Aerosphere approved in China for patients with COPD astrazeneca.com ↗ |
| 2019-08-28 | AstraZeneca | Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease astrazeneca.com ↗ |
| 2018-05-16 | AstraZeneca | AstraZeneca is advancing clinical practice in respiratory medicine with new data at the American Thoracic Society 2018 International Congress astrazeneca.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glycopyrrolate/Formoterol | “Effects of Glycopyrrolate/Formoterol (Bevespi) on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI” NCT03324607 ↗ |
| Known as | Bevespi | “Effects of Glycopyrrolate/Formoterol (Bevespi) on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI” NCT03324607 ↗ |